Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - cetylpyridinium chloride, quantity: 1.4 mg; benzocaine, quantity: 10 mg - lozenge - excipient ingredients: ascorbyl palmitate; palm fruit oil; purified water; oleyl oleate; sunset yellow fcf; sucrose; light liquid paraffin; liquid glucose; brilliant blue fcf; medium chain triglycerides; coconut oil; quinoline yellow; dl-alpha-tocopherol; flavour - anaesthetic/antibacterial lozenges for symptomatic relief of sore throats.

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - cetylpyridinium chloride, quantity: 1.47 mg; benzyl alcohol, quantity: 6.5 mg - lozenge - excipient ingredients: liquid glucose; ascorbyl palmitate; dl-alpha-tocopherol; oleyl oleate; light liquid paraffin; caramel; coconut oil; purified water; sucrose; medium chain triglycerides; palm fruit oil; flavour - antibacterial lozenges for symptomatic relief of sore throats

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - benzocaine, quantity: 8 mg - lozenge - excipient ingredients: mannitol; polysorbate 80; acesulfame potassium; sucralose; macrogol 6000; hypromellose; macrogol 400; xanthan gum; purified water; magnesium stearate; titanium dioxide; flavour - anaesthetic lozenges for symptomatic relief of sore throats

Canada - English - Health Canada

fresenius kabi canada ltd - flumazenil - solution - 0.1mg - flumazenil 0.1mg - miscellaneous central nervous system agents

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil 0.1 mg in 1 ml - flumazenil is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil is indicated for the reversal of conscious sedation induced with benzodiazepines. (see precautions–pediatric use .) flumazenil is contraindicated: - in patients with a known hypersensitivity to flumazenil or benzodiazepines. - in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (eg, control of intracranial pressure or status epilepticus). - in patients who are showing signs of serious cyclic antidepressant overdose. (see warnings .) flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in animal models, produces dyspho

United States - English - NLM (National Library of Medicine)

sandoz inc - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil 0.1 mg in 1 ml - flumazenil injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil injection is indicated for the reversal of conscious sedation induced with benzodiazepines (see precautions: pediatric use ). flumazenil injection is contraindicated: - in patients with a known hypersensitivity to flumazenil or benzodiazepines. - in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (eg, control of intracranial pressure or status epilepticus). - in patients who are showing signs of serious cyclic antidepressant overdose (see warnings ). flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in a

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil 0.1 mg in 1 ml - flumazenil injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil injection is indicated for the reversal of conscious sedation induced with benzodiazepines (see precautions: pediatric use ). flumazenil injection is contraindicated: flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in animal models, produces dysphoria in normal subjects, and has had no reported abuse in foreign marketing. although flumazenil has a benzodiazepine-like structure it does not act as a benzodiazepine agonist in man and is not a controlled substance.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; water for injections; sodium hydroxide; glacial acetic acid - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide; disodium edetate; glacial acetic acid; sodium chloride - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

United States - English - NLM (National Library of Medicine)

sina health inc - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil 0.1 mg in 1 ml - flumazenil injection, usp is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil injection, usp is indicated for the reversal of conscious sedation induced with benzodiazepines (see precautions: pediatric use ). flumazenil is contraindicated: - in patients with a known hypersensitivity to flumazenil or benzodiazepines. - in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). - in patients who are showing signs of serious cyclic antidepressant overdose (see warnings ). flumazenil acts as a benzodiazepine antagonist, blocks the effect of benzodiazepines in animals and man, antagonizes b